Abstract 4035
Background
Breast cancer is one of the most common malignant disease for women. Mammography is the preferred method for breast cancer detection. The purpose is to investigate the feasibility and accuracy of texture features extracted from digital mammograms at predicting benign and malignant breast mass using Radiomics.
Methods
494 digital mammograms data who diagnosed as breast masses (Benign: 251 Malignant: 243) by mammography were enrolled. Enrol criteria: breast masses classified as BI-RADS 3, 4, and 5 and at last confirmed by histopathology. Lesion area was marked with a rectangular frame on the Cranio-Caudal (CC) and MedioLateral Oblique (MLO) images at the 5M workstation. The rectangular regions of interest (ROI) was segmented and 456 radiomics features were extracted from every ROI. Extracted features were dimensioned by Maximum Relevance Minimum Redundancy (MRMR) and Lasso algorithm. Post-dimension features were classified using Support Vector Machine (SVM). 70% of the data as a training set and the other 30% as a testing set. The reliability of the Classifier was evaluated by the 10-fold cross-validation. The classification accuracy was evaluated by the accuracy and sensitivity and AUC.
Results
Both the MRMR and Lasso screened 30 radiomics features respectively. 10-fold cross-validation showed that their accuracy were 88.70% and 86.71%, respectively. In testing sets, Through the MRMR algorithm, the classifier achieves an accuracy of 92.00% and a sensitivity of 91.10% and AUC of 95.10%. Through the lasso dimension reduction algorithm, the classifier achieves an accuracy of 83.26% and a sensitivity of 75.90% and AUC of 89.38%.
Conclusions
Radiomics texture features from digital mammograms may be used for benign and malignant prediction. This method offer better accuracy and sensitivity. It is expected to provide an auxiliary diagnosis for the imaging doctors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5056 - Phase 2 study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
5710 - Avelumab for advanced Merkel cell carcinoma in the Netherlands; a nationwide survey
Presenter: Sonja Levy
Session: Poster Display session 3
Resources:
Abstract
3152 - Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data
Presenter: Sandra D'Angelo
Session: Poster Display session 3
Resources:
Abstract
5715 - A Phase 2, Randomized Study of Nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and Stereotactic Body Radiation Therapy (SBRT) for Metastatic Merkel Cell Carcinoma (MCC, NCT03071406) – a preliminary report.
Presenter: Sungjune Kim
Session: Poster Display session 3
Resources:
Abstract
2854 - Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma
Presenter: Kalijn Bol
Session: Poster Display session 3
Resources:
Abstract
2928 - Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients
Presenter: Mathilde Saint-Ghislain
Session: Poster Display session 3
Resources:
Abstract
1235 - Incidence and survival of Uveal Melanoma occurring as single cancer versus its occurrence as a first or second primary neoplasm
Presenter: Ahmad Alfaar
Session: Poster Display session 3
Resources:
Abstract
3615 - Validation of a Clinicopathological and Gene Expression Profile (CP-GEP) Model for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
Presenter: Evalyn Mulder
Session: Poster Display session 3
Resources:
Abstract
1793 - External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the Surveillance, Epidemiology and End Results (SEER) Program
Presenter: Angelina Tjokrowidjaja
Session: Poster Display session 3
Resources:
Abstract
4278 - Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts).
Presenter: Ines Pires da Silva
Session: Poster Display session 3
Resources:
Abstract